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In colorectal cancer (CRC), hepatic arterial infusion (HAI) chemotherapy may convert primarily unresectable CRC liver metastases
(CLM) into resectability, although the risk of metastatic recurrence remains high after CLM ablation. We investigated the role of
antitumour immunity invoked by first-line oxaliplatin-HAI for long-term CLM outcome. In a prospective study cohort of primarily
unresectable CLM, we assessed patients’ fms-related tyrosine kinase 3 ligand (FLT3LG) in serum, reflecting opportune
intratumoural immune activity, at baseline and following 1–3 sequences of oxaliplatin-HAI. The end points were CLM resectability
and overall survival. Patients who presented an immediate twofold increment of circulating FLT3LG during the treatment and at its
completion were scored as CLM resectable (16.4% with both features), were alive at final follow-up 8–12 years later. All patients
experienced FLT3LG increase during the treatment course, but those who remained unresectable or had the disease converted but
presented a slow and gradual FLT3LG accretion, later died of the metastatic disease. These data provide further support to our
previous findings that tumour-directed immunity invoked by oxaliplatin-containing therapy predicts excellent outcome of early
advanced CRC if macroscopic tumour ablation is rendered possible by the ‘classic’ tumour response to the cytotoxic treatment.
Additional Supporting Information may be found in the online
version of this article.
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Introduction
In colorectal cancer (CRC), dissemination into systemic disease
remains the main therapeutic challenge. Improved surgical tech-
niques1,2 and the introduction of perioperative oxaliplatin-based
chemotherapy3,4 have enabled an increasing number of patients
with liver-confined metastatic disease to undergo treatment with
potentially curative intent, although metastatic recurrence
occurs in a high percentage of cases. In terms of response rates
for initially unresectable CRC liver metastases (CLM), the best
outcomes in randomised trials have been observed for
oxaliplatin-containing triplet regimens5,6 with favourable long-
term results for both resected and nonresected patients.7–9
Hence, primarily unresectable CLM may be converted into
resectability after sufficient response to chemotherapy,10 but
deliberate patient selection is crucial for survival benefits.11,12
Metastatic lesions in the liver are predominantly supplied by
the hepatic artery.13,14 The technique of therapeutic hepatic arterial
infusion (HAI) was developed to deliver an antineoplastic agent at
high concentration directly into the liver metastases without caus-
ing systemic toxicity.15,16 Oxaliplatin exhibits favourable
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pharmacokinetic characteristics for a HAI regimen due to the high
first-pass hepatic extraction rate.17,18 Early-phase or retrospective
studies have investigated the concept of using oxaliplatin as the
HAI compound for isolated unresectable CLM with treatment tox-
icity, tumour response and survival as end points.19–22 Only one
prospective study has reported the intent to transform to resectable
disease, in this case by HAI administration of triplet oxaliplatin-
containing chemotherapy, which resulted in hepatectomy for 30%
of patients.23 The role of HAI chemotherapy in clinical practice
still remains controversial, but trials that randomise between this
and modern systemic therapy are ongoing.24,25
As a result of the tumour cell cytotoxicity, oxaliplatin
elicits immunogenic cell death (ICD), which implies that the
shed tumour antigens are captured by dendritic cells for sub-
sequent priming of tumour-targeting T-cells.26,27 The majority
of CRC cases are not inherently immunogenic28,29 but might,
if transformed to such a state by oxaliplatin, be subject to
improved systemic immune surveillance with reduced risk of
disease progression.30 Our study on patients with locally
advanced rectal cancer at high metastatic risk, given intensi-
fied oxaliplatin-containing therapy before radical surgery,31
led to an ICD conceptual discovery. Patients who experienced
a pronounced rise in serum levels of the fms-related tyrosine
kinase 3 ligand (FLT3LG) during the neoadjuvant treatment
course, interpreted as ICD induction, had significantly better
progression-free survival than those without such response,
implying that an advantageous systemic immune response
might have been invoked by oxaliplatin.32 The FLT3LG is a
potent growth factor for antigen-presenting dendritic cells33,34
and when administered to patients with metastatic CRC, has
led to expansion of the dendritic cell population both locally
in tumour and systematically.35 In melanoma, which is the
archetype immunogenic tumour entity, it was recently dem-
onstrated that intratumoural natural killer cells are the source
of the dendritic cell-stimulatory FLT3LG.36
Because FLT3LG in the systemic circulation may reflect an
immune response generated within the tumour microenviron-
ment, we hypothesised it may be used in the context of
predicting long-term outcome of first-line oxaliplatin-HAI in
patients with primarily unresectable CLM.
Materials and Methods
Ethics and approvals
The study was approved by the Committee for Research Ethics
of the Capital Region of Denmark (reference number H-KA-
04043-GS; the 5th of May, 2004) and the Danish Medicines
Agency (reference number 2612-2538; the 16th of November,
2004), and was conducted in accordance with the Declaration
of Helsinki. Besides these mandatory approvals, there was no
requirement for trial registration in a public registry when our
study started patient accrual in 2004, nor for preceding Institu-
tional Review Board evaluation within the Danish specialist
health services. Written informed consent by each patient was
required for participation. In January 2018, anonymized bio-
bank samples linked to de-identified selected patient data were
transferred from Herlev and Gentofte Hospital, Denmark, to
Akershus University Hospital, Norway, in accordance with cur-
rent regulations.
Study design, treatment and end points
In this nonrandomised phase 2 study, eligible patients presented
with their first recurrence of oxaliplatin-naïve isolated CLM origi-
nating from CRC adenocarcinoma and considered technically
unresectable.37 As delineated in Figure 1, patients were given a
dose-intensified regimen of HAI-oxaliplatin (100 mg/m2) on Day
1 and high-dose oral capecitabine (1,750 mg/m2 twice daily) on
Day 1–7 every 2 weeks for a maximum of 12 cycles, in accor-
dance with a dose administration regimen described in 2003.38
The study treatment was terminated sooner if patients experi-
enced intolerable toxicity or disease progression, or after 8 cycles
if objective radiographic response had failed to occur. Treatment
response was evaluated every 4 cycles (defined as one treatment
sequence). Patients who at any evaluation (after 4, 8 or 12 treat-
ment cycles) were considered qualified for a CLM ablation
procedure with either radiofrequency ablation or hepatic re-
section proceeded to the planned treatment option, after which
the study protocol specified 6 cycles or 3 months of postoperative
systemic therapy consisting of oxaliplatin (85 mg/m2) on Day
1 and capecitabine (1,750 mg/m2 twice daily) on Day 1–7 every
2 weeks. Patients with CLM that did not become resectable via
the study treatment proceeded to irinotecan-based chemotherapy.
CLM resectability (resectable or unresectable), irrespective of the
number of HAI cycles, was the primary end point (along with the
response rate37). The overall survival rate at censoring, recorded
on the 8th of February, 2018, was a secondary end point. The pre-
sent study subpopulation of 55 patients was enrolled between the
14th of December, 2004 and the 7th of October, 2009. Primary
tumour RAS mutational status was determined retrospectively in
a two-step procedure consisting of KRAS exon 2 analysis by the
therascreen® test (Qiagen) followed by targeted DNA sequencing
What’s new?
In colorectal cancer (CRC), hepatic arterial infusion (HAI) chemotherapy may convert primarily unresectable CRC liver
metastases (CLM) into resectable CLM. The risk of metastatic recurrence remains high, however, and molecular markers for
long-term therapeutic benefit are needed. In this prospective cohort study of patients who received oxaliplatin-HAI, the authors
assessed serum FLT3LG to monitor intratumoural immune activity. All patients experienced FLT3LG increase during therapy, but
only those who experienced a rapid and substantial tumour-directed immune response were alive 8–12 years later. Monitoring
the immune response via serum FLT3LG may improve the selection of CLM patients for a curative-intent ablation procedure.
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(by the Ion AmpliSeq Cancer Hotspot Panel v2; Thermo Fisher
Scientific) of the wild-type KRAS exon 2 specimens.
Assessment of serum FLT3LG
Patients had study-specific serum sampled at baseline (immedi-
ately before commencement of treatment; n = 55) and after
each sequence of study treatment (at each evaluation), defined
as post-1st seq (after 4 cycles; n = 43), post-2nd seq (after
8 cycles; n = 33) and post-3rd seq (after 12 cycles; n = 26). Sam-
ples were no longer collected after patients were definitely con-
cluded as CLM resectable or unresectable, and patients could
occasionally miss out from sampling of reasons unrelated to the
study conduct. Blood was drawn in plain serum tubes with no
additives for centrifugation to separate serum, which was left in
room temperature for no more than 2 hr before storage at
−80C. Analysis of FLT3LG was undertaken in February–
March 2018 (i.e. after 101–158 months of storage) using a
customised Luminex Multiplex Assay (R&D Systems, Boston,
MA), following the manufacturer’s instructions. This is a bead-
based technology for assessment of multiple serum analytes.
The manufacturer advises against the use of measures outside
the standard curve (below 70% of the lowest value and above
130% of the highest value of the standard curve). In the case of
the FLT3LG analysis, all of the reported measurements were
within these assay constraints. The mean value of duplicate
measures was used in downstream analyses. One other analyte
of potential relevance in the oxaliplatin-induced ICD context39
was assayed simultaneously and will be reported separately.
Statistical analysis
The analyses were performed using the SAS software version 9.4
and STATA version 15. Differences in mean baseline serum
FLT3LG values and in CLM resectability scores between various
patient and tumour characteristics were analysed by independent
samples t-test, χ2-test or Fisher’s exact test, as appropriate. Since
our hypothesis was that serum FLT3LG during the oxaliplatin-
HAI therapy might predict treatment outcome (CLM resectability
and survival at censoring), we estimated linear mixed models
assessing the longitudinal change of FLT3LG (as continuous vari-
able) within the defined outcome groups. First, the overall trend
in FLT3LG response over the treatment course in the entire
patient cohort was estimated by a linear mixed model with fixed
effects for the time of measurement. Next, the trend in FLT3LG
response in the defined outcome groups was assessed by linear
mixed models with fixed effects for the time of measurement,
group and interaction between the time of measurement and
group. All models included random effects for patients to cor-
rectly adjust the estimates for within-patient correlations due to
repeated measurements. Between-group differences at each mea-
surement were derived from the estimated linear mixed models
in post hoc analyses. The results were presented as mean differ-
ence with 95% confidence interval (CI). Moreover, Cox propor-
tional hazards models were estimated to assess the hazard ratio
with 95% CI for overall survival for increasing values of FLT3LG
measured at the single time points. An extended Cox regression
model for survival was estimated with FLT3LG as time-dependent
covariate. All time-dependent outcomes were calculated from the
date of study enrolment. Results with p values below 0.05 were
considered statistically significant. All tests were two-sided.
Data availability
Request to inspect and analyse the data that underlie the results
reported in this article should be directed to the corresponding
author, and access will be provided in accordance with the
General Data Protection Regulation of the European Union.
Results
Patient characteristics and circulating FLT3LG
As shown in Table 1, the 55 patients (64% males) had a mean age
of 60 (minimum, maximum: 41, 74) years, of whom 48 reported
normal performance status [Eastern Cooperative Oncology
Group (ECOG) score40 0]. Eighty percent of primary tumours
were left-sided or rectal, and half of the cases had mutant RAS
status (7 of 11 right-sided and 20 of 44 left-sided/rectal cases).
With the exception of significantly lower measures for the seven
patients with reduced performance status (ECOG score 1–2),
Figure 1. The study design, treatment and primary end point. Each circle indicates the start (by means of hepatic arterial infusion of
oxaliplatin) of a therapy cycle (horizontal arrow), protocol-planned to every 2 weeks, with 4 cycles defining a treatment sequence. Vertical
arrows indicate treatment evaluation and study-specific serum sampling [at baseline and after 4 therapy cycles (Post-1st seq), 8 cycles (Post-
2nd seq) and 12 cycles (Post-3rd seq)]. The numbers of treated patients in each sequence and patients within the two groups of the primary
end point (CLM, colorectal liver metastases) at each treatment evaluation are given.
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baseline FLT3LG values did not differ between the various patient
and tumour strata (listed in Table 1). For the whole patient group
(Fig. 2), FLT3LG showed an initial increase before a less marked
continuous rise and a final slight decline, with measures
(mean  standard deviation; in pg/ml) of 75.9  23.5 at baseline,
133.5  53.8 at post-1st seq, 147.3  53.4 at post-2nd seq and
128.7  37.0 at post-3rd seq.
CLM resectability and patient survival
As indicated in Figure 1, two patients had disease progression
at post-1st seq and five others had progression or no objective
response at post-2nd seq; hence, seven patients were scored as
CLM unresectable based on the criterion of failed treatment
response over the initial 4–8 cycles. In addition, 15 patients
were scored as technically unresectable at post-3rd seq despite
a radiographic response. In contrast, two patients had the
CLM converted to resectable disease at post-1st seq, another
three at post-2nd seq and yet 28 at post-3rd seq, altogether of
whom 30 proceeded to CLM ablation because three patients
with complete treatment response remained radiologically free
of disease.
Among the 33 patients who were scored as CLM resectable
(60.0% of enrolled individuals) and thus, might be cured of
their metastatic disease, 9 (27.3%) were alive at censoring,
resulting in an overall survival rate of 16.4% for the total study
population. Median time to death was 71.0 (minimum, maxi-
mum: 22.0, 147.0) months for patients in the resectable cate-
gory as opposed to 23.5 (minimum, maximum: 5.0, 63.0)
months for patients who remained with unresectable CLM.
The median follow-up time for the nine patients alive was
122.0 (minimum, maximum: 100.0, 144.7) months—the oldest
study patient was 87 years old at censoring.
FLT3LG and treatment outcome
In order to explore the serum FLT3LG response over the treat-
ment course (Fig. 2), patients were stratified according to treat-
ment outcome (CLM resectability and survival at censoring)
and linear mixed models were estimated, with the results dis-
played in Figure 3. The significant overall trend in the FLT3LG
response (p < 0.001; upper panel) was essentially reproduced
within the short-term outcome groups, with no trend difference
between resectable and unresectable cases (middle panel). The
distribution of age, sex and primary tumour sidedness was also
equal in resectable and unresectable cases, while tumour wild-
type RAS status was significantly more common in patients who
had the disease converted to resectability (Supporting Informa-
tion Table S1).
As illustrated by the lower panel of Figure 3, the overall
trend of the serum FLT3LG response differed (p = 0.005) for
patients in the resectable category who were alive (n = 9) or
dead (n = 24) at censoring. The patients in this category who
later died, all but three of metastatic recurrence, presented an
almost constant and altogether less than twofold increment of
FLT3LG over the entire treatment course. In contrast, the sur-
viving individuals (i.e. those cured of the metastatic disease by
the multimodal study treatment) had an immediate twofold
FLT3LG increase from mean 76.5 (95% CI: 50.8–102.3) pg/ml
at baseline to mean 158.9 (95% CI: 136.3–181.6) pg/ml at
post-1st seq before a continued rise to mean 179.6 (95% CI:
156.7–202.5) pg/ml at post-2nd seq. The relative incline over
the second treatment sequence, however, was essentially simi-
lar to that in the patient group that later died. At completion
of the maximum number of therapy cycles (post-3rd seq), the
two patient groups again had identical circulating FLT3LG
values, which for the surviving individuals were a consequence
Table 1. Baseline characteristics of the cohort
n (%)
FLT3LG, pg/ml
Mean (SD) p1
Age, years Mean
(minimum, maximum)
60 (41, 74)
Sex
Male 35 (63.6) 77.6 (25.1)
Female 20 (36.4) 72.8 (20.7) 0.47
ECOG performance status
0 48 (87.3) 78.9 (21.6)
1–2 7 (12.7) 55.4 (27.6) 0.01
Primary tumour location
Right-sided 11 (20.0) 71.7 (18.5)
Left-sided or rectal 44 (80.0) 76.9 (24.7) 0.52
Tumour RAS status
Wild-type 28 (50.9) 81.7 (24.3)
Mutant 27 (49.1) 69.9 (21.6) 0.06
1By independent samples t-test.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLT3LG, fms-
related tyrosine kinase 3 ligand; SD, standard deviation.
Figure 2. Serum levels of fms-related tyrosine kinase 3 ligand
(FLT3LG) during the study treatment [at baseline (n = 55) and after
4 therapy cycles (Post-1st seq; n = 43), 8 cycles (Post-2nd seq;
n = 33) and 12 cycles (Post-3rd seq; n = 26)]. The horizontal line in
each data cluster represents the mean value.
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of a decline over the third treatment sequence. However,
among the resectable cases, none of FLT3LG values at any
point of measurement over the treatment course was predic-
tive of overall survival, nor were the longitudinal FLT3LG
measures entered into the model simultaneously for all indi-
vidual patients within the total study population (Supporting
Information Table S2).
Post hoc analyses (Table 2) showed that in the group of
resectable cases, the early rise in circulating FLT3LG in patients
who were alive at censoring translated into mean differences
relative to those who later died of 39.6 (95% CI: 12.3–66.9)
pg/ml (p = 0.004) at post-1st seq and 39.5 (95% CI: 11.8–67.3)
pg/ml (p = 0.005) at post-2nd seq. The differences at comple-
tion of the first and second treatment sequences were essen-
tially also seen within the total study population when
comparing the nine surviving individuals with the 46 patients
who died. Additionally, patients scored with unresectable CLM
after three therapy sequences had serum FLT3LG values that
were lower than the measures in resectable cases by a small
margin, with a mean difference of 31.0 (95% CI: 0.10–61.8)
pg/ml (p = 0.049).
Discussion
In order to improve the selection of patients with isolated, pri-
marily unresectable CLM for curative-intent ablation after che-
motherapy, a better understanding of the underlying biology
and the development of molecular markers for long-term ther-
apeutic benefit are needed.41 We noted that patients who dur-
ing first-line oxaliplatin-HAI presented a rapid and substantial
rise in circulating FLT3LG over the initial treatment, regarded
as a marker of invoked tumour-defeating immunity,32–34 and
at treatment completion could proceed to CLM ablation, were
alive at final follow-up 8–12 years later. Essentially, all study
patients experienced serum FLT3LG increase after start of the
therapy. However, 40% of cases did not have the CLM
converted to resectable disease, and more than 70% of those
who were finally scored as technically resectable presented a
slow and gradual FLT3LG accretion. The patients with either
of these features died in the study follow-up. Consequently,
complete tumour eradication appeared to be contingent on
conversion to resectable disease (for macroscopic tumour
clearance) along with a manifest antitumour immune response
(for elimination of disseminated microscopic tumour cells).
Liver-confined disease represents about one-third of meta-
static CRC cases, with complete macroscopic ablation consid-
ered an option for potential cure.42 However, recurrent
disease occurs in the majority of patients, and even with
Figure 3. Serum levels of fms-related tyrosine kinase 3 ligand
(FLT3LG) during the study treatment [at baseline and after 4 therapy
cycles (Post-1st seq), 8 cycles (Post-2nd seq) and 12 cycles (Post-
3rd seq)] in all study patients (upper panel) and patients stratified to
treatment outcome groups [colorectal liver metastases resectability
(resectable, unresectable; middle panel) and survival at censoring
(alive, dead) for the resectable cases (lower panel)]. Results of linear
mixed models; means and 95% confidence intervals.
Table 2. Differences in serum FLT3LG during the study treatment
between patients with various outcomes
Outcome
Point of
measurement
FLT3LG, pg/ml
Mean difference
(95% CI)1 p1
Resectable versus
unresectable
Post-3rd seq 31.0 (0.10–61.8) 0.049
Alive versus dead
(within the
resectable
patient category)
Post-1st seq 39.6 (12.3–66.9) 0.004
Post-2nd seq 39.5 (11.8–67.3) 0.005
Alive versus dead
(within the total
study population)
Post-1st seq 32.3 (5.70–58.9) 0.017
Post-2nd seq 36.6 (9.60–63.6) 0.008
1Results of post hoc analyses.
Abbreviations: CI, confidence interval; FLT3LG, fms-related tyrosine kinase
3 ligand; Post-1st seq, after 4 therapy cycles; Post-2nd seq, after 8 therapy
cycles; Post-3rd seq, after 12 therapy cycles.
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contemporary multimodal treatment only one in five patients
is cured.42,43 Primary tumour right-sidedness and mutant RAS
status have been reported as unfavourable prognostic fac-
tors.44,45 The current study population displayed distributions
of age, sex and tumour sidedness and mutational status in
agreement with other reports on isolated CLM.20,21,23,46 We
observed that wild-type RAS status was strongly associated
with CLM conversion to resectability by oxaliplatin-HAI. The
significantly longer overall survival for those patients has been
reported previously.37
Oxaliplatin-based chemotherapy administered systemically
is considered the standard-of-care for the majority of CLM
patients, particularly if conversion of technically unresectable
disease to resectability is the primary goal.10 Prospective stud-
ies of oxaliplatin-HAI in combination with a systemically
administered fluoropyrimidine, given either as early-line ther-
apy or after failure of systemic palliative therapy, have
reported various response and survival rates.22 Modern onco-
logical approaches have yielded median overall survival of
unselected patients with metastatic CRC of approximately
30 months.10 The randomised FIRE-3 trial on chemotherapy
combined with biologically targeted agents in the first line for
metastatic CRC showed median overall survival of 36 months
for patients with wild-type RAS liver-confined disease.47 In
the present study, 60% of cases were converted to resectability
and had median overall survival of close to 6 years. More than
one quarter of the resected patients were cured. Altogether,
these are remarkable results for patients with disseminated
CRC, providing additional evidence to the importance of opti-
mal patient selection and treatment approaches in organ-
limited disease. We acknowledge that eligible study patients, a
high percentage of whom had normal performance status, had
their first metastatic event and thus were selected for good
prognosis. Yet, for both the resected and nonresected patient
groups, disease recurrence or progression seemed to be domi-
nant, warranting a deeper understanding of the involved bio-
logical mechanisms in order to further improve the cure rate.
From experimental models it has long been known that
FLT3LG is central in the development of distinct subsets of
dendritic cell lineages48 and that this factor, in combination
with tumour irradiation, causes long-term protective anti-
tumour immunity.49 This knowledge has fostered the recent
enthusiasm for administering FLT3LG together with radio-
therapy as an in situ vaccination strategy in combination with
immune checkpoint-blocking therapy, in order to obtain sys-
temic therapeutic effects.34 In the present analysis, we found
that intratumoural delivery of oxaliplatin caused FLT3LG
release into the circulation, supporting the notion that
oxaliplatin may promote an intratumoural immune response
that specifically recruits dendritic cells to present antigens
released by the dying tumour cells to cytotoxic lymphocytes,
ultimately providing systemic immunity. The likely freedom
from recurrent metastasis in CLM-ablated patients who had
experienced a rapid initial rise in circulating FLT3LG during
the oxaliplatin-HAI therapy appears to agree with the theory
that FLT3LG production reflects an innate immune response,
specifically comprising natural killer cells, within the tumour
microenvironment.36
However, genuine cure of the metastatic disease was addi-
tionally contingent on therapeutic conversion to resectability
as a result of the ‘classic’ cytotoxic effect of chemotherapy.
We made a corresponding observation in study patients with
locally advanced rectal cancer at high metastatic risk, treated
with neoadjuvant oxaliplatin and radiotherapy before radical
surgery.31 Those who had an immediate rise in circulating
FLT3LG during the neoadjuvant course were cured after pel-
vic tumour clearance enabled by sufficient tumour regression
after the cytotoxic therapy.32 Within this frame of reference,
it is tempting to speculate whether patients in the present
study who presented an insufficient FLT3LG accretion, yet
achieved CLM resectability, might have obtained long-term
survival from the addition of immune checkpoint-blocking
therapy.
There are obvious limitations of this spin-off study. First,
the cohort is small, without a control group. However, this is
our second study reporting on oxaliplatin effects on circulat-
ing FLT3LG and the advantageous outcome of early advanced
CRC. Next, a number of serum samples were missing and
FLT3LG could not be consecutively followed for all of the
patients. Moreover, the analyses were undertaken without
information about dose adjustments or accounting for com-
mon predictors of CLM outcome such as the location, number
and size of liver lesions42 but comprised the study’s main pri-
mary and secondary end points.
In conclusion, our study provides indications that systemic
tumour-directed immunity invoked under chemotherapy pre-
dicts excellent outcome of isolated CLM if macroscopic
tumour ablation is rendered possible by the ‘classic’ tumour
response to the cytotoxic therapy. Information about the cir-
culating FLT3LG profile over the course of treatment may be
useful for the selection of patients with primarily unresectable
CLM most likely to benefit from a curative-intent ablation
procedure.
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